Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2024 10:26 ET | Source: Willis Towers Watson US LLC

Commercial insurance market projects stability as rates moderate across most lines of business

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- According to the latest Insurance Marketplace Realities report from WTW (Willis Towers Watson, NASDAQ: WTW), a leading global advisory, broking and...
October 09, 2024 10:00 ET | Source: Hydrofarm Holdings Group, Inc.

Hydrofarm Holdings Group, Inc. Announces Fireside Chat with Water Tower Research

SHOEMAKERSVILLE, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded...
October 09, 2024 09:47 ET | Source: SEALSQ

SEALSQ Getting Ready for the Arrival of Quantum Computers as Post-Quantum Cryptographic Algorithms and Semiconductors are the Front-Line of defense Against Adversarial Quantum Attacks

Geneva, Switzerland, Oct. 09, 2024 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum...
October 09, 2024 09:20 ET | Source: StepStone Group Inc

StepStone Private Wealth Surpasses $5 Billion in AUM Milestone

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- StepStone Private Wealth (“SPW”) today announced it has surpassed $5 billion in global assets under management, making it one of the fastest growing...
October 09, 2024 09:19 ET | Source: VCI Global Limited

VCI Global Unleashes Enterprise AI Solutions with V-Gallant, Leveraging NVIDIA’s Computing Infrastructure

KUALA LUMPUR, Malaysia, Oct. 09, 2024 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (Frankfurt: H0T) (“VCI Global” or the “Company”), through its subsidiary, V Gallant Sdn Bhd (“V-Gallant”),...
October 09, 2024 09:18 ET | Source: Inhibikase Therapeutics

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase...
October 09, 2024 09:15 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
October 09, 2024 09:15 ET | Source: Capricor Therapeutics

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
October 09, 2024 09:15 ET | Source: La Rosa Holdings Corp.

La Rosa Holdings Launches My Agent Account Version 3.0 with Enhanced Property Management Disbursement Features; Expected to Enhance La Rosa's Agents' Productivity and Efficiency by 50% by Year-End

Celebration, FL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for six agent-centric, technology-integrated, cloud-based,...
October 09, 2024 09:05 ET | Source: Longeveron

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.